Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medivir AB ( (SE:MVIR) ) has provided an update.
Medivir AB has called an extraordinary general meeting for 14 January 2026 at its Huddinge headquarters, giving shareholders the option to participate and exercise their voting rights in person, by proxy or via postal voting, in line with its articles of association. The notice details the record date for voting eligibility, procedures for nominee-registered shareholders to secure temporary voting rights registration, and practical instructions and deadlines for registering attendance or submitting postal votes, underscoring the company’s adherence to Swedish corporate governance standards and efforts to facilitate broad shareholder participation.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish publicly listed pharmaceutical company based in Huddinge, focused on research and development of innovative therapies, with its shares registered and handled through Euroclear Sweden’s systems for Swedish securities.
Average Trading Volume: 961,184
Technical Sentiment Signal: Sell
Current Market Cap: SEK157.9M
For a thorough assessment of MVIR stock, go to TipRanks’ Stock Analysis page.